Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- Ann: Race releases complete cardio-protection data & video
Yes to an extent as the price that will ultimately be able to be...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.61 |
Change
0.000(0.00%) |
Mkt cap ! $273.5M |
Open | High | Low | Value | Volume |
$1.62 | $1.62 | $1.61 | $20.46K | 12.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 1460 | $1.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.61 | 2460 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1587 | 1.605 |
3 | 1447 | 1.600 |
1 | 5148 | 1.585 |
3 | 2932 | 1.580 |
2 | 9000 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.615 | 2202 | 1 |
1.620 | 2000 | 1 |
1.645 | 9982 | 2 |
1.650 | 37731 | 2 |
1.670 | 754 | 1 |
Last trade - 10.12am 09/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online